(Total Views: 577)
Posted On: 04/07/2025 5:13:41 PM
Post# of 154604
Trodelvy vs. leronlimab in mTNBC
Trodelvy had a complete response rate of 3.7% at 29.6 months.
There has to be at least two patients cancer free at 36 months that's 7.1%. If there's 3 that's 10.7%. Maybe more?
Additionally Cytodyn was hampered a bit in this trial. Trodelvy did not accept patients with brain metastasis at the beginning of the trial but leronlimab did. Of more significance 9 patients were treated with 350mg (4 were upgraded to 525mg), 16 patients had 525mg and only 3 patients had 700mg. The majority were underdosed.
Ihttps://www.nejm.org/doi/full/10.1056/NEJMoa2028485
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e13062
Trodelvy had a complete response rate of 3.7% at 29.6 months.
Quote:
In addition, the Company confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease.
There has to be at least two patients cancer free at 36 months that's 7.1%. If there's 3 that's 10.7%. Maybe more?
Additionally Cytodyn was hampered a bit in this trial. Trodelvy did not accept patients with brain metastasis at the beginning of the trial but leronlimab did. Of more significance 9 patients were treated with 350mg (4 were upgraded to 525mg), 16 patients had 525mg and only 3 patients had 700mg. The majority were underdosed.
Ihttps://www.nejm.org/doi/full/10.1056/NEJMoa2028485
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e13062
(21)
(0)
